{"description":"Documents matching 'sermorelin'","count":34,"total_pages":2,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=sermorelin&format=json&page=2","results":[{"title":"HISA Anti-Doping and Medication Control Rule","type":"Notice","abstract":"The Horseracing Integrity and Safety Act of 2020 recognizes a self-regulatory nonprofit organization, the Horseracing Integrity and Safety Authority, which is charged with developing proposed rules on a variety of subjects. Those proposed rules and later proposed rule modifications take effect only if approved by the Federal Trade Commission. The proposed rules and rule modifications must be published in the Federal Register for public comment. Thereafter, the Commission has 60 days from the date of publication to approve or disapprove the proposed rule or rule modification. The Authority submitted to the Commission a proposed rule on Anti-Doping and Medication Control on December 30, 2022. The Office of the Secretary of the Commission determined that the proposal complied with the Commission's rule governing such submissions. This document publicizes the Authority's proposed rule's text and explanation, and it seeks public comment on whether the Commission should approve or disapprove the proposed rule. This document is substantially similar to the document published on October 28, 2022, as corrected on November 4, 2022, and the Commission will consider all comments filed in response to that document as well as all comments filed in response to this document.","document_number":"2023-00957","html_url":"https://www.federalregister.gov/documents/2023/01/26/2023-00957/hisa-anti-doping-and-medication-control-rule","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-01-26/pdf/2023-00957.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-00957.pdf?1674654316","publication_date":"2023-01-26","agencies":[{"raw_name":"FEDERAL TRADE COMMISSION","name":"Federal Trade Commission","id":192,"url":"https://www.federalregister.gov/agencies/federal-trade-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/192","parent_id":null,"slug":"federal-trade-commission"}],"excerpts":"conjugated) in urine. \n \n \n CONTROLLED \n S7 \n A \n Secobarbital (Quinalbarbitone) \n Sedative/Hypnotic \n Discontinued, no FDA-approved product commercially available. DEA Schedule II \n \n \n BANNED \n S0 \n \n Selegiline \n Antidepressant \n Emsam, Zelapar \n \n \n BANNED \n S2 \n \n <span class=\"match\">Sermorelin</span> \n Growth Hormone \n Discontinued, no FDA-approved product commercially available \n \n \n BANNED \n S0 \n \n Sertraline \n Antidepressant \n Zoloft \n \n \n BANNED \n S0 \n \n Sibutramine \n Stimulant \n Discontinued, no FDA-approved product commercially available. DEA Schedule IV \n \n "},{"title":"HISA Anti-Doping and Medication Control Rule","type":"Notice","abstract":"The Horseracing Integrity and Safety Act of 2020 recognizes a self-regulatory nonprofit organization, the Horseracing Integrity and Safety Authority, which is charged with developing proposed rules on a variety of subjects. Those proposed rules and later proposed rule modifications take effect only if approved by the Federal Trade Commission. The proposed rules and rule modifications must be published in the Federal Register for public comment. Thereafter, the Commission has 60 days from the date of publication to approve or disapprove the proposed rule or rule modification. The Authority submitted to the Commission a proposed rule on Anti-Doping and Medication Control on August 17, 2022 and supplemented on October 13, 2022. The Office of the Secretary of the Commission determined that the proposal complied with the Commission's rule governing such submissions. This document publicizes the Authority's proposed rule text and explanation, and it seeks public comment on whether the Commission should approve or disapprove the proposed rule.","document_number":"2022-22970","html_url":"https://www.federalregister.gov/documents/2022/10/28/2022-22970/hisa-anti-doping-and-medication-control-rule","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-10-28/pdf/2022-22970.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-22970.pdf?1666874715","publication_date":"2022-10-28","agencies":[{"raw_name":"FEDERAL TRADE COMMISSION","name":"Federal Trade Commission","id":192,"url":"https://www.federalregister.gov/agencies/federal-trade-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/192","parent_id":null,"slug":"federal-trade-commission"}],"excerpts":"conjugated) in urine. \n \n \n CONTROLLED \n S7 \n A \n Secobarbital (Quinalbarbitone) \n Sedative/Hypnotic \n Discontinued, no FDA-approved product commercially available. DEA Schedule II \n \n \n BANNED \n S0 \n \n Selegiline \n Antidepressant \n Emsam, Zelapar \n \n \n BANNED \n S2 \n \n <span class=\"match\">Sermorelin</span> \n Growth Hormone \n Discontinued, no FDA-approved product commercially available \n \n \n BANNED \n S0 \n \n Sertraline \n Antidepressant \n Zoloft \n \n \n BANNED \n S0 \n \n Sibutramine \n Stimulant \n Discontinued, no FDA-approved product commercially available. DEA Schedule IV \n \n "},{"title":"Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Short Inpatient Hospital Stays; Transition for Certain Medicare-Dependent, Small Rural Hospitals Under the Hospital Inpatient Prospective Payment System; Provider Administrative Appeals and Judicial Review","type":"Rule","abstract":"This final rule with comment period revises the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2016 to implement applicable statutory requirements and changes arising from our continuing experience with these systems. In this final rule with comment period, we describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. In addition, this final rule with comment period updates and refines the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program. Further, this document includes certain finalized policies relating to the hospital inpatient prospective payment system: Changes to the 2- midnight rule under the short inpatient hospital stay policy; and a payment transition for hospitals that lost their status as a Medicare- dependent, small rural hospital (MDH) because they are no longer in a rural area due to the implementation of the new Office of Management and Budget delineations in FY 2015 and have not reclassified from urban to rural before January 1, 2016. In addition, this document contains a final rule that finalizes certain 2015 proposals, and addresses public comments received, relating to the changes in the Medicare regulations governing provider administrative appeals and judicial review relating to appropriate claims in provider cost reports.","document_number":"2015-27943","html_url":"https://www.federalregister.gov/documents/2015/11/13/2015-27943/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2015-11-13/pdf/2015-27943.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2015-27943.pdf?1446236131","publication_date":"2015-11-13","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"Fludarabine phosphate, oral, 10 mg \n E \n \n \n J9160 \n Injection, denileukin diftitox, 300 micrograms \n E \n \n \n J9215 \n Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu \n E \n \n \n J9300 \n Injection, gemtuzumab ozogamicin, 5 mg \n E \n \n \n Q0515 \n Injection, <span class=\"match\">sermorelin</span> acetate, 1 microgram \n E \n \n \n Q9980 \n Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg \n E \n \n \n C. Self-Administered Drugs (SADs) Technical Correction \n Sections 1861(s)(2)(A) and (s)(2)(B) of the Act define covered “medical and other health"},{"title":"Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Short Inpatient Hospital Stays; Transition for Certain Medicare-Dependent, Small Rural Hospitals Under the Hospital Inpatient Prospective Payment System","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2016 to implement applicable statutory requirements and changes arising from our continuing experience with these systems. In this proposed rule, we describe the proposed changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. In addition, this proposed rule would update and refine the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program. Further, this proposed rule includes certain proposals relating to the hospital inpatient prospective payment system: proposed changes to the 2-midnight rule under the short inpatient hospital stay policy, as well as a discussion of the related -0.2 percent payment adjustment; and a proposed transition for Medicare-dependent, small rural hospitals located in all-urban States.","document_number":"2015-16577","html_url":"https://www.federalregister.gov/documents/2015/07/08/2015-16577/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2015-07-08/pdf/2015-16577.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2015-16577.pdf?1435781725","publication_date":"2015-07-08","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"diphosphate, 250 mg \n E \n \n \n J9213 \n Injection, interferon, alfa-2a, recombinant, 3 million units \n E \n \n \n J9215 \n Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu \n E \n \n \n J9300 \n Injection, gemtuzumab ozogamicin, 5 mg \n E \n \n \n Q0515 \n Injection, <span class=\"match\">sermorelin</span> acetate, 1 microgram \n E \n \n \n \n C. Self-Administered Drugs (SADs) Technical Correction \n Sections 1861(s)(2)(A) and (s)(2)(B) of the Act define covered “medical and other health services” to include both “services and supplies” and “hospital services”, which both, in turn"},{"title":"Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness","type":"Notice","abstract":"The Food and Drug Administration (FDA) has determined that GEREF (Sermorelin Acetate) injection, 0.5 milligrams (mg) base/vial and 1.0 mg base/vial, and GEREF (Sermorelin Acetate) injection, 0.05 mg base/amp, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for GEREF (Sermorelin Acetate) injection, 0.5 mg base/vial and 1.0 mg base/vial, and GEREF (Sermorelin Acetate) injection, 0.05 mg base/amp, if all other legal and regulatory requirements are met.","document_number":"2013-04827","html_url":"https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-04827.pdf?1362145737","publication_date":"2013-03-04","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"SUMMARY: \n \n The Food and Drug Administration (FDA) has determined that GEREF (<span class=\"match\">Sermorelin</span> Acetate) \n \n injection, 0.5 milligrams (mg) base/vial and 1.0 mg base/vial, and GEREF (<span class=\"match\">Sermorelin</span> Acetate) injection, 0.05 mg base/amp, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for GEREF (<span class=\"match\">Sermorelin</span> Acetate) injection, 0.5 mg base/vial and 1.0 mg base/vial, and GEREF (<span class=\"match\">Sermorelin</span> Acetate) injection, 0.05 mg base/amp, if all other legal and regulatory requirements"},{"title":"Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Physician-Owned Hospitals: Data Sources for Expansion Exception; Physician Certification of Inpatient Hospital Services; Medicare Advantage Organizations and Part D Sponsors: CMS-Identified Overpayments Associated with Submitted Payment Data","type":"Rule","abstract":"This final rule with comment period revises the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2015 to implement applicable statutory requirements and changes arising from our continuing experience with these systems. In this final rule with comment period, we describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. In addition, this final rule with comment period updates and refines the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program. In this document, we also are making changes to the data sources permitted for expansion requests for physician-owned hospitals under the physician self-referral regulations; changes to the underlying authority for the requirement of an admission order for all hospital inpatient admissions and changes to require physician certification for hospital inpatient admissions only for long-stay cases and outlier cases; and changes to establish a formal process, including a three- level appeals process, to recoup overpayments that result from the submission of erroneous payment data by Medicare Advantage (MA) organizations and Part D sponsors in the limited circumstances in which the organization or sponsor fails to correct these data.","document_number":"2014-26146","html_url":"https://www.federalregister.gov/documents/2014/11/10/2014-26146/medicare-and-medicaid-programs-hospital-outpatient-prospective-payment-and-ambulatory-surgical","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2014-11-10/pdf/2014-26146.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2014-26146.pdf?1414787533","publication_date":"2014-11-10","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"\n E \n \n \n Q0174 \n Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen \n E \n \n \n Q0515 \n Injection, <span class=\"match\">sermorelin</span> acetate, 1 microgram \n E \n \n \n \n VI. Estimate of OPPS Transitional Pass-Through Spending for Drugs, Biologicals, Radiopharmaceuticals, and Devices \n A. Background \n Section 1833(t)(6)(E) of the Act limits the total projected amount of transitional pass-through payments"},{"title":"Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Physician-Owned Hospitals: Data Sources for Expansion Exception; Physician Certification of Inpatient Hospital Services; Medicare Advantage Organizations and Part D Sponsors: Appeals Process for Overpayments Associated With Submitted Data","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2015 to implement applicable statutory requirements and changes arising from our continuing experience with these systems. In this proposed rule, we describe the proposed changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. In addition, this proposed rule would update and refine the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program. In this document, we also are proposing changes to the data sources used for expansion requests for physician owned hospitals under the physician self-referral regulations; changes to the underlying authority for the requirement of an admission order for all hospital inpatient admissions and changes to require physician certification for hospital inpatient admissions only for long-stay cases and outlier cases; and changes to establish a three-level appeals process for Medicare Advantage (MA) organizations and Part D sponsors that would be applicable to CMS-identified overpayments associated with data submitted by these organizations and sponsors.","document_number":"2014-15939","html_url":"https://www.federalregister.gov/documents/2014/07/14/2014-15939/medicare-and-medicaid-programs-hospital-outpatient-prospective-payment-and-ambulatory-surgical","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2014-07-14/pdf/2014-15939.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2014-15939.pdf?1404418332","publication_date":"2014-07-14","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"\n E \n \n \n Q0174 \n Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen \n E \n \n \n Q0515 \n Injection, <span class=\"match\">sermorelin</span> acetate, 1 microgram \n E \n \n \n VI. Proposed Estimate of OPPS Transitional Pass-Through Spending for Drugs, Biologicals, Radiopharmaceuticals, and Devices \n A. Background \n Section 1833(t)(6)(E) of the Act limits the total projected amount of transitional pass-through payments"},{"title":"Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Hospital Value-Based Purchasing Program; Organ Procurement Organizations; Quality Improvement Organizations; Electronic Health Records (EHR) Incentive Program; Provider Reimbursement Determinations and Appeals","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2014 to implement applicable statutory requirements and changes arising from our continuing experience with these systems. In this proposed rule, we describe the proposed changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. In addition, this proposed rule would update and refine the requirements for the Hospital Outpatient Quality Reporting (OQR) Program, the ASC Quality Reporting (ASCQR) Program, and the Hospital Value-Based Purchasing (VBP) Program. We are proposing changes to the conditions for coverage (CfCs) for organ procurement organizations (OPOs); revisions to the Quality Improvement Organization (QIO) regulations; changes to the Medicare fee-for-service Electronic Health Record (EHR) Incentive Program; and changes relating to provider reimbursement determinations and appeals.","document_number":"2013-16555","html_url":"https://www.federalregister.gov/documents/2013/07/19/2013-16555/medicare-and-medicaid-programs-hospital-outpatient-prospective-payment-and-ambulatory-surgical","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-07-19/pdf/2013-16555.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-16555.pdf?1373314331","publication_date":"2013-07-19","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"Nabilone, oral, 1 mg \n 4 \n K \n 1424 \n \n \n J9216 \n Injection, interferon, gamma 1-b, 3 million units \n 1 \n K \n 0838 \n \n \n J9226 \n Histrelin implant (supprelin la), 50 mg \n 1 \n K \n 1142 \n \n \n J9300 \n Injection, gemtuzumab ozogamicin, 5 mg \n 1 \n K \n 9004 \n \n \n Q0515 \n Injection, <span class=\"match\">sermorelin</span> acetate, 1 microgram \n 70 \n K \n 3050 \n \n \n Finally, there were 11 drugs and biologicals, shown in Table 27, that were payable in CY 2012 but for which we lacked CY 2012 claims data and any other pricing information for the ASP methodology for this CY 2014 OPPS/ASC proposed"},{"title":"Hospital Outpatient Prospective and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Electronic Reporting Pilot; Inpatient Rehabilitation Facilities Quality Reporting Program; Quality Improvement Organization Regulations","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2013 to implement applicable statutory requirements and changes arising from our continuing experience with these systems. In this proposed rule, we describe the proposed changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. In addition, we are proposing updates and refinements to the requirements for the Hospital Outpatient Quality Reporting (OQR) Program, the ASC Quality Reporting (ASCQR) Program, and the Inpatient Rehabilitation Facility (IRF) Quality Reporting Program. We also are proposing revisions to the electronic reporting pilot for the Electronic Health Record (EHR) Incentive Program, and the various regulations governing Quality Improvement Organizations (QIOs), including the secure transmittal of electronic medical information, beneficiary complaint resolution and notification processes, and technical changes.","document_number":"2012-16813","html_url":"https://www.federalregister.gov/documents/2012/07/30/2012-16813/hospital-outpatient-prospective-and-ambulatory-surgical-center-payment-systems-and-quality-reporting","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2012-07-30/pdf/2012-16813.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2012-16813.pdf?1341605829","publication_date":"2012-07-30","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"J9151 \n Injection, daunorubicin citrate, liposomal formulation, 10 mg \n 5 \n K \n 0821 \n \n \n J0205 \n Injection, alglucerase, per 10 units \n 420 \n K \n 0900 \n \n \n J2724 \n Injection, protein c concentrate, intravenous, human, 10 iu \n 1540 \n K \n 1139 \n \n \n Q0515 \n Injection, <span class=\"match\">sermorelin</span> acetate, 1 microgram \n 70 \n K \n 3050 \n \n \n J2513 \n Injection, pentastarch, 10% solution, 100 ml \n 4 \n N \n N/A \n \n \n J3355 \n Injection, urofollitropin, 75 IU \n 2 \n K \n 1741 \n \n \n 90581 \n Anthrax vaccine, for subcutaneous or intramuscular use \n 1 \n K \n 1422 \n \n \n J2265 \n"},{"title":"Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment; Ambulatory Surgical Center Payment; Hospital Value-Based Purchasing Program; Physician Self-Referral; and Provider Agreement Regulations on Patient Notification Requirements","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system (OPPS) to implement applicable statutory requirements and changes arising from our continuing experience with this system. In this proposed rule, we describe the proposed changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the OPPS. These proposed changes would be applicable to services furnished on or after January 1, 2012. In addition, this proposed rule would update the revised Medicare ambulatory surgical center (ASC) payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. In this proposed rule, we set forth the proposed relative payment weights and payment amounts for services furnished in ASCs, specific HCPCS codes to which these proposed changes would apply, and other proposed ratesetting information for the CY 2012 ASC payment system. These proposed changes would be applicable to services furnished on or after January 1, 2012. We are proposing to revise the requirements for the Hospital Outpatient Quality Reporting (IQR) Program, add new requirements for ASC Quality Reporting System, and make additional changes to provisions of the Hospital Inpatient Value-Based Purchasing (VBP) Program. We also are proposing to allow eligible hospitals and CAHs participating in the Medicare Electronic Health Record (EHR) Incentive Program to meet the clinical quality measure reporting requirement of the EHR Incentive Program for payment year 2012 by participating in the 2012 Medicare EHR Incentive Program Electronic Reporting Pilot. In addition, we are proposing to make changes to the rules governing the whole hospital and rural provider exceptions to the physician self-referral prohibition for expansion of facility capacity and changes to provider agreement regulations on patient notification requirements.","document_number":"2011-16949","html_url":"https://www.federalregister.gov/documents/2011/07/18/2011-16949/medicare-and-medicaid-programs-hospital-outpatient-prospective-payment-ambulatory-surgical-center","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2011-07-18/pdf/2011-16949.pdf","public_inspection_pdf_url":null,"publication_date":"2011-07-18","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"4 \n K \n 1222 \n \n \n J2724 \n Injection, protein c concentrate, intravenous, human, 10 iu \n 1540 \n K \n 1139 \n \n \n J3355 \n Injection, urofollitropin, 75 IU \n 2 \n K \n 1741 \n \n \n J9216 \n Injection, interferon, gamma 1-b, 3 million units \n 1 \n K \n 0838 \n \n \n Q0515 \n Injection, <span class=\"match\">sermorelin</span> acetate, 1 microgram \n 70 \n K \n 3050 \n \n \n Finally, there were five drugs and biologicals, shown in Table 34 below, that were payable in CY 2010, but for which we lacked CY 2010 claims data and any other pricing information for the ASP methodology for the CY 2012 OPPS/ASC"},{"title":"Medicare Program: Hospital Outpatient Prospective Payment System and CY 2011 Payment Rates; Ambulatory Surgical Center Payment System and CY 2011 Payment Rates; Payments to Hospitals for Graduate Medical Education Costs; Physician Self-Referral Rules and Related Changes to Provider Agreement Regulations; Payment for Certified Registered Nurse Anesthetist Services Furnished in Rural Hospitals and Critical Access Hospitals","type":"Rule","abstract":"The final rule with comment period in this document revises the Medicare hospital outpatient prospective payment system (OPPS) to implement applicable statutory requirements and changes arising from our continuing experience with this system and to implement certain provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (Affordable Care Act). In this final rule with comment period, we describe the changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes are applicable to services furnished on or after January 1, 2011. In addition, this final rule with comment period updates the revised Medicare ambulatory surgical center (ASC) payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system and to implement certain provisions of the Affordable Care Act. In this final rule with comment period, we set forth the applicable relative payment weights and amounts for services furnished in ASCs, specific HCPCS codes to which these changes apply, and other pertinent ratesetting information for the CY 2011 ASC payment system. These changes are applicable to services furnished on or after January 1, 2011. In this document, we also are including two final rules that implement provisions of the Affordable Care Act relating to payments to hospitals for direct graduate medical education (GME) and indirect medical education (IME) costs; and new limitations on certain physician referrals to hospitals in which they have an ownership or investment interest. In the interim final rule with comment period that is included in this document, we are changing the effective date for otherwise eligible hospitals and critical access hospitals that have been reclassified from urban to rural under section 1886(d)(8)(E) of the Social Security Act and 42 CFR 412.103 to receive reasonable cost payments for anesthesia services and related care furnished by nonphysician anesthetists from cost reporting periods beginning on or after October 1, 2010, to December 2, 2010.","document_number":"2010-27926","html_url":"https://www.federalregister.gov/documents/2010/11/24/2010-27926/medicare-program-hospital-outpatient-prospective-payment-system-and-cy-2011-payment-rates-ambulatory","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2010-11-24/pdf/2010-27926.pdf","public_inspection_pdf_url":null,"publication_date":"2010-11-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"1268 \n \n \n J9215 \n Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu \n 5 \n K \n 0865 \n \n \n J9226 \n Histrelin implant (supprelin la), 50 mg \n 1 \n K \n 1142 \n \n \n J9357 \n Injection, valrubicin, intravesical, 200 mg \n 4 \n K \n 1235 \n \n \n Q0515 \n Injection, <span class=\"match\">sermorelin</span> acetate, 1 microgram \n 70 \n K \n 3050 \n \n \n Q2017 \n Injection, teniposide, 50 mg \n 9.35 \n K \n 7035 \n \n \n Finally, there were five drugs and biologicals, shown in Table 36 below, that were payable in CY 2009, but for which we lacked CY 2009 claims data and any other pricing"},{"title":"Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications","type":"Notice","abstract":"The Food and Drug Administration (FDA) is withdrawing approval of 92 new drug applications (NDAs) and 49 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.","document_number":"E9-11628","html_url":"https://www.federalregister.gov/documents/2009/05/19/E9-11628/novartis-pharmaceuticals-corp-et-al-withdrawal-of-approval-of-92-new-drug-applications-and-49","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2009-05-19/pdf/E9-11628.pdf","public_inspection_pdf_url":null,"publication_date":"2009-05-19","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"\n \n \n NDA 19-775 \n Minipress XL (prazosin HCl) Extended-Release Tablets \n Pfizer, Inc. \n \n \n NDA 19-794 \n Depakote CP (divalproex sodium) Delayed-Release Tablets \n Abbott Laboratories, 200 Abbott Park Rd., Abbott Park, IL 60664-6157 \n \n \n NDA 19-863 \n Geref Diagnostic (<span class=\"match\">sermorelin</span> acetate) for Injection \n EMD Serono, Inc., One Technology Dr., Rockland, MA 02370 \n \n \n NDA 19-983 \n Prostep (nicotine) Transdermal System, 11 mg/24 hour (h) and 22 mg/24 h \n Aveva Drug Delivery Systems, Inc., 3250 Commerce Pkwy., Miramar, FL 33025 \n \n \n NDA 20-013 \n Maxaquin"},{"title":"Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates, the Ambulatory Surgical Center Payment System and CY 2008 Payment Rates, the Hospital Inpatient Prospective Payment System and FY 2008 Payment Rates; and Payments for Graduate Medical Education for Affiliated Teaching Hospitals in Certain Emergency Situations Medicare and Medicaid Programs: Hospital Conditions of Participation; Necessary Provider Designations of Critical Access Hospitals; Correction","type":"Rule","abstract":"This document corrects technical errors that appeared in the final rule with comment period published in the Federal Register (FR) on November 27, 2007, entitled \"Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates, the Ambulatory Surgical Center Payment System and CY 2008 Payment Rates, the Hospital Inpatient Prospective Payment System and FY 2008 Payment Rates; and Payments for Graduate Medical Education for Affiliated Teaching Hospitals in Certain Emergency Situations Medicare and Medicaid Programs: Hospital Conditions of Participation; Necessary Provider Designations of Critical Access Hospitals.\"","document_number":"08-671","html_url":"https://www.federalregister.gov/documents/2008/02/22/08-671/medicare-program-changes-to-the-hospital-outpatient-prospective-payment-system-and-cy-2008-payment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2008-02-22/pdf/08-671.pdf","public_inspection_pdf_url":null,"publication_date":"2008-02-22","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"Q0174 \n Thiethylperazine maleate 10mg \n \n N1 \n \n \n \n \n Q0175 \n Perphenazine 4mg oral \n \n N1 \n \n \n \n \n Q0177 \n Hydroxyzine pamoate 25mg \n \n N1 \n \n \n \n \n Q0179 \n Ondansetron HCl 8mg oral \n \n K2 \n \n $18.37 \n \n \n Q0180 \n Dolasetron mesylate oral \n \n K2 \n \n $43.77 \n \n \n Q0515 \n <span class=\"match\">Sermorelin</span> acetate injection \n \n K2 \n \n $1.74 \n \n \n Q1003 \n Ntiol category 3 \n \n L6 \n \n $50.00 \n \n \n Q2004 \n Bladder calculi irrig sol \n \n N1 \n \n \n \n \n Q2009 \n Fosphenytoin, 50 mg \n \n K2 \n \n $5.76 \n \n \n Q2017 \n Teniposide, 50 mg \n \n K2 \n \n $280.26 \n \n \n Q3025 \n IM inj interferon beta"},{"title":"Medicare Program: Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates, the Ambulatory Surgical Center Payment System and CY 2008 Payment Rates, the Hospital Inpatient Prospective Payment System and FY 2008 Payment Rates; and Payments for Graduate Medical Education for Affiliated Teaching Hospitals in Certain Emergency Situations Medicare and Medicaid Programs: Hospital Conditions of Participation; Necessary Provider Designations of Critical Access Hospitals","type":"Rule","abstract":"This final rule with comment period revises the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. We describe the changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes are applicable to services furnished on or after January 1, 2008. In addition, the rule sets forth the applicable relative payment weights and amounts for services furnished in ASCs, specific HCPCS codes to which the final policies of the ASC payment system apply, and other pertinent rate setting information for the CY 2008 ASC payment system. Furthermore, this final rule with comment period will make changes to the policies relating to the necessary provider designations of critical access hospitals and changes to several of the current conditions of participation requirements. The attached document also incorporates the changes to the FY 2008 hospital inpatient prospective payment system (IPPS) payment rates made as a result of the enactment of the TMA, Abstinence Education, and QI Programs Extension Act of 2007, Public Law 110-90. In addition, we are changing the provisions in our previously issued FY 2008 IPPS final rule and are establishing a new policy, retroactive to October 1, 2007, of not applying the documentation and coding adjustment to the FY 2008 hospital-specific rates for Medicare-dependent, small rural hospitals (MDHs) and sole community hospitals (SCHs). In the interim final rule with comment period in this document, we are modifying our regulations relating to graduate medical education (GME) payments made to teaching hospitals that have Medicare affiliation agreements for certain emergency situations.","document_number":"07-5507","html_url":"https://www.federalregister.gov/documents/2007/11/27/07-5507/medicare-program-changes-to-the-hospital-outpatient-prospective-payment-system-and-cy-2008-payment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2007-11-27/pdf/07-5507.pdf","public_inspection_pdf_url":null,"publication_date":"2007-11-27","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":" K \n \n $126.44 \n \n $25.29 \n \n \n 2940 \n Somatrem injection \n K \n \n $168.90 \n \n $33.78 \n \n \n 3030 \n Sumatriptan succinate \n K \n \n $61.27 \n \n $12.25 \n \n \n 3041 \n Bivalirudin \n K \n \n $1.84 \n \n $0.37 \n \n \n 3043 \n Gamma globulin 1 CC inj \n K \n \n $11.91 \n \n $2.38 \n \n \n 3050 \n <span class=\"match\">Sermorelin</span> acetate injection \n K \n \n $1.74 \n \n $0.35 \n \n \n 7000 \n Amifostine \n K \n \n $490.93 \n \n $98.19 \n \n \n 7005 \n Gonadorelin hydroch \n K \n \n $178.59 \n \n $35.72 \n \n \n 7011 \n Oprelvekin injection \n K \n \n $247.02 \n \n $49.40 \n \n \n 7015 \n Oral busulfan \n K \n \n $2.26 \n \n $0.45 \n \n "},{"title":"Medicare Program: Proposed Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates; Proposed Changes to the Ambulatory Surgical Center Payment System and CY 2008 Payment Rates; Medicare and Medicaid Programs: Proposed Changes to Hospital Conditions of Participation; Proposed Changes Affecting Necessary Provider Designations of Critical Access Hospitals","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. In this proposed rule, we describe the proposed changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes would be applicable to services furnished on or after January 1, 2008. In addition, this proposed rule would update the revised Medicare ambulatory surgical center (ASC) payment system to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). In this proposed rule, we propose the applicable relative payment weights and amounts for services furnished in ASCs, specific HCPCS codes to which the final policies of the ASC payment system would apply, and other pertinent ratesetting information for the CY 2008 ASC payment system. These changes would be applicable to services furnished on or after January 1, 2008. In this proposed rule, we also are proposing changes to the policies relating to the necessary provider designations of critical access hospitals (CAHs) that are being recertified when a CAH enters into a new co-location arrangement with another hospital or CAH or when the CAH creates or acquires an off-campus location. Further, we are proposing changes to several of the current conditions of participation that hospitals must meet to participate in the Medicare and Medicaid programs to require the completion and documentation in the medical record of medical histories and physical examinations of patients conducted after admission and prior to surgery or a procedure requiring anesthesia services and for postanesthesia evaluations of patients before discharge or transfer from the postanesthesia recovery area.","document_number":"07-3509","html_url":"https://www.federalregister.gov/documents/2007/08/02/07-3509/medicare-program-proposed-changes-to-the-hospital-outpatient-prospective-payment-system-and-cy-2008","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2007-08-02/pdf/07-3509.pdf","public_inspection_pdf_url":null,"publication_date":"2007-08-02","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"70 \n \n $23.34 \n \n \n 2940 \n Somatrem injection \n K \n 1.0916 \n $69.53 \n \n $13.91 \n \n \n 3030 \n Sumatriptan succinate/6 MG \n K \n \n $58.82 \n \n $11.76 \n \n \n 3041 \n Bivalirudin \n K \n \n $1.72 \n \n $0.34 \n \n \n 3043 \n Gamma globulin 1 CC inj \n K \n \n $11.31 \n \n $2.26 \n \n \n \n 3050 \n <span class=\"match\">Sermorelin</span> acetate injection \n K \n \n $1.74 \n \n $0.35 \n \n \n 7000 \n Amifostine \n K \n \n $476.10 \n \n $95.22 \n \n \n 7005 \n Gonadorelin hydroch/100 mcg \n K \n \n $178.59 \n \n $35.72 \n \n \n 7011 \n Oprelvekin injection \n K \n \n $244.98 \n \n $49.00 \n \n \n 7015 \n Oral busulfan \n K \n \n $2.12 \n \n $0"},{"title":"Medicare Program; Revised Payment System Policies for Services Furnished in Ambulatory Surgical Centers (ASCs) Beginning in CY 2008","type":"Rule","abstract":"This final rule revises the Medicare ambulatory surgical center (ASC) payment system to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). This final rule establishes the ASC list of covered surgical procedures, identifies covered ancillary services under the revised ASC payment system, and sets forth the amounts and factors that will be used to determine the ASC payment rates for calendar year (CY) 2008. The changes to the ASC payment system and ratesetting methodology in this final rule are applicable to services furnished on or after January 1, 2008.","document_number":"07-3490","html_url":"https://www.federalregister.gov/documents/2007/08/02/07-3490/medicare-program-revised-payment-system-policies-for-services-furnished-in-ambulatory-surgical","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2007-08-02/pdf/07-3490.pdf","public_inspection_pdf_url":null,"publication_date":"2007-08-02","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"\n Q0174 \n Thiethylperazine maleate 10 mg \n N1 \n \n \n \n \n Q0175 \n Perphenazine 4 mg oral \n N1 \n \n \n \n \n Q0177 \n Hydroxyzine pamoate 25 mg \n N1 \n \n \n \n \n Q0179 \n Ondansetron HCl 8 mg oral \n K2 \n \n $36.55 \n \n \n Q0180 \n Dolasetron mesylate oral \n K2 \n \n $47.52 \n \n \n Q0515 \n <span class=\"match\">Sermorelin</span> acetate injection \n K2 \n \n $1.75 \n \n \n Q1003 \n Ntiol category 3 \n L6 \n \n $50.00 \n \n \n Q2004 \n Bladder calculi irrig sol \n N1 \n \n \n \n \n Q2009 \n Fosphenytoin, 50 mg \n K2 \n \n $5.66 \n \n \n Q2017 \n Teniposide, 50 mg \n K2 \n \n $264.09 \n \n \n Q3025 \n IM inj interferon beta 1-a \n"},{"title":"Medicare Program; Hospital Outpatient Prospective Payment System and CY 2007 Payment Rates; CY 2007 Update to the Ambulatory Surgical Center Covered Procedures List; Medicare Administrative Contractors; and Reporting Hospital Quality Data for FY 2008 Inpatient Prospective Payment System Annual Payment Update Program-HCAHPS Survey, SCIP, and Mortality","type":"Rule","abstract":"This final rule with comment period revises the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system, and to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 and the Deficit Reduction Act (DRA) of 2005. In this final rule with comment period, we describe changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes are applicable to services furnished on or after January 1, 2007. In addition, this final rule with comment period implements future CY 2009 required reporting on quality measures for hospital outpatient services paid under the prospective payment system. This final rule with comment period revises the current list of procedures that are covered when furnished in a Medicare-approved ambulatory surgical center (ASC), which are applicable to services furnished on or after January 1, 2007. This final rule with comment period revises the emergency medical screening requirements for critical access hospitals (CAHs). This final rule with comment period supports implementation of a restructuring of the contracting entities responsibilities and functions that support the adjudication of Medicare fee-for-service (FFS) claims. This restructuring is directed by section 1874A of the Act, as added by section 911 of the MMA. The prior separate Medicare intermediary and Medicare carrier contracting authorities under Title XVIII of the Act have been replaced with the Medicare Administrative Contractor (MAC) authority. This final rule continues to implement the requirements of the DRA that require that we expand the \"starter set\" of 10 quality measures that we used in FY 2005 and FY 2006 for the hospital inpatient prospective payment system (IPPS) Reporting Hospital Quality Data for the Annual Payment Update (RHQDAPU) program. We began to adopt expanded measures effective for payments beginning in FY 2007. In this rule, we are finalizing additional quality measures for the expanded set of measures for FY 2008 payment purposes. These measures include the HCAHPS survey, as well as Surgical Care Improvement Project (SCIP, formerly Surgical Infection Prevention (SIP)), and Mortality quality measures.","document_number":"06-9079","html_url":"https://www.federalregister.gov/documents/2006/11/24/06-9079/medicare-program-hospital-outpatient-prospective-payment-system-and-cy-2007-payment-rates-cy-2007","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2006-11-24/pdf/06-9079.pdf","public_inspection_pdf_url":null,"publication_date":"2006-11-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":" K \n \n 10.49 \n \n 2.10 \n \n \n 3043 \n Gamma globulin 1 CC inj \n K \n \n 10.34 \n \n 2.07 \n \n \n 3045 \n Meropenem \n K \n \n 3.68 \n \n 0.74 \n \n \n \n 3048 \n Doxorubic hcl 10 MG vl chemo \n K \n \n 6.00 \n \n 1.20 \n \n \n 3049 \n Cyclophosphamide lyophilized \n K \n \n 5.72 \n \n 1.14 \n \n \n 3050 \n <span class=\"match\">Sermorelin</span> acetate injection \n K \n \n 1.75 \n \n 0.35 \n \n \n 7000 \n Amifostine \n K \n \n 463.27 \n \n 92.65 \n \n \n 7005 \n Gonadorelin hydroch/ 100 mcg \n K \n \n 189.84 \n \n 37.97 \n \n \n 7011 \n Oprelvekin injection \n K \n \n 245.98 \n \n 49.20 \n \n \n 7015 \n Oral busulfan \n K \n \n 2.14 \n \n 0.43 \n \n \n"},{"title":"Medicare Program; Hospital Outpatient Prospective Payment System and CY 2007 Payment Rates; CY 2007 Update to the Ambulatory Surgical Center Covered Procedures List; Ambulatory Surgical Center Payment System and CY 2008 Payment Rates; Medicare Administrative Contractors; and Reporting Hospital Quality Data for FY 2008 Inpatient Prospective Payment System Annual Payment Update Program-HCAHPS® Survey, SCIP, and Mortality","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system, and to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003, and the Deficit Reduction Act (DRA) of 2005. The proposed rule describes proposed changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes would be applicable to services furnished on or after January 1, 2007. In addition, this proposed rule would revise the current list of procedures that are approved when furnished in a Medicare-approved ambulatory surgical center (ASC), which would be applicable to services furnished on or after January 1, 2007. Further, this proposed rule would revise the ASC facility payment system to implement provisions of the MMA and other applicable statutory requirements, and update the ASC payment rates. Changes to the ASC facility payment system and the payment rates would be applicable to services furnished on or after January 1, 2008. This proposed rule would revise the emergency medical screening requirements for critical access hospitals (CAHs). In addition, this proposed rule would support implementation of a restructuring of the contracting entities responsibilities and functions that support the adjudication of Medicare fee-for-service (FFS) claims. This restructuring is directed by section 1874A of the Act, as added by section 911 of the MMA. The prior separate Medicare intermediary and Medicare carrier contracting authorities under Title XVIII of the Act have been replaced with the Medicare Administrative Contractor (MAC) authority. This proposed rule would also continue to implement the requirements of the DRA that require that we expand the \"starter set\" of 10 quality measures that we used in FY 2005 and FY 2006 for the hospital Inpatient Prospective Payment System (IPPS) Reporting Hospital Quality Data for the Annual Payment Update (RHQDAPU) program. We began to adopt expanded measures effective for payments beginning in FY 2007. We are proposing to add additional quality measures to the expanded set of measures for FY 2008 payment purposes. These measures include the HCAHPS[supreg] survey, as well as Surgical Care Improvement Project (SCIP, formerly Surgical Infection Prevention (SIP)), and Mortality quality measures.","document_number":"06-6846","html_url":"https://www.federalregister.gov/documents/2006/08/23/06-6846/medicare-program-hospital-outpatient-prospective-payment-system-and-cy-2007-payment-rates-cy-2007","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2006-08-23/pdf/06-6846.pdf","public_inspection_pdf_url":null,"publication_date":"2006-08-23","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"3.76 \n \n 0.75 \n \n \n 3046 \n Octreotide inj, non-depot \n K \n \n 4.34 \n \n 0.87 \n \n \n 3047 \n Melphalan oral 2 MG \n K \n \n 4.39 \n \n 0.88 \n \n \n 3048 \n Doxorubic hcl 10 MG vl chemo \n K \n \n 6.23 \n \n 1.25 \n \n \n 3049 \n Cyclophosphamide lyophilized \n K \n \n 5.47 \n \n 1.09 \n \n \n 3050 \n <span class=\"match\">Sermorelin</span> acetate injection \n K \n \n 1.73 \n \n 0.35 \n \n \n 7000 \n Amifostine \n K \n \n 448.41 \n \n 89.68 \n \n \n 7005 \n Gonadorelin hydroch/ 100 mcg \n K \n \n 178.59 \n \n 35.72 \n \n \n 7011 \n Oprelvekin injection \n K \n \n 243.39 \n \n 48.68 \n \n \n 7015 \n Oral busulfan \n K \n \n 1.95 \n \n 0.39 \n \n \n"},{"title":"Medicare Program; Proposed Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2006 Payment Rates; Correction","type":"Proposed Rule","abstract":"This document corrects technical errors that appeared in the proposed rule published in the Federal Register on July 25, 2005 entitled \"Medicare Program; Proposed Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2006 Payment Rates; Proposed Rule.\"","document_number":"05-16699","html_url":"https://www.federalregister.gov/documents/2005/08/26/05-16699/medicare-program-proposed-changes-to-the-hospital-outpatient-prospective-payment-system-and-calendar","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2005-08-26/pdf/05-16699.pdf","public_inspection_pdf_url":null,"publication_date":"2005-08-26","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"Fosphenytoin, 50 mg \n 7028 \n \n $5.19 \n \n $1.04 \n \n \n Q2011 \n K \n \n Hemin, per 1 mg \n 7030 \n \n $6.51 \n \n $1.30 \n \n \n Q2012 \n K \n \n Pegademase bovine, 25 iu \n 9168 \n \n $161.16 \n \n $32.23 \n \n \n Q2013 \n K \n \n Pentastarch 10% solution \n 7040 \n \n $12.45 \n \n $2.49 \n \n \n Q2014 \n N \n \n <span class=\"match\">Sermorelin</span> acetate, 0.5 mg \n \n \n \n \n \n \n \n Q2017 \n K \n \n Teniposide, 50 mg \n 7035 \n \n $266.23 \n \n $53.25 \n \n \n Q2018 \n K \n \n Urofollitropin, 75 iu \n 7037 \n \n $44.74 \n \n $8.95 \n \n \n Q2019 \n K \n \n Basiliximab \n 1615 \n \n $1,473.57 \n \n $294.71 \n \n \n Q2020 \n E \n \n Histrelin acetate \n "},{"title":"Medicare Program; Proposed Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2006 Payment Rates","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system and to implement certain related provisions of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003. In addition, the proposed rule describes proposed changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. This proposed rule would also change the requirement for physician oversight of mid-level practitioners in critical access hospitals (CAHs). These changes would be applicable to services furnished on or after January 1, 2006.","document_number":"05-14448","html_url":"https://www.federalregister.gov/documents/2005/07/25/05-14448/medicare-program-proposed-changes-to-the-hospital-outpatient-prospective-payment-system-and-calendar","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2005-07-25/pdf/05-14448.pdf","public_inspection_pdf_url":null,"publication_date":"2005-07-25","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"Fosphenytoin, 50 mg \n 7028 \n \n $5.19 \n \n $1.04 \n \n \n Q2011 \n K \n \n Hemin, per 1 mg \n 7030 \n \n $6.51 \n \n $1.30 \n \n \n Q2012 \n K \n \n Pegademase bovine, 25 iu \n 9168 \n \n $161.15 \n \n $32.23 \n \n \n Q2013 \n K \n \n Pentastarch 10% solution \n 7040 \n \n $12.45 \n \n $2.49 \n \n \n Q2014 \n N \n \n <span class=\"match\">Sermorelin</span> acetate, 0.5 mg \n \n \n \n \n \n \n \n Q2017 \n K \n \n Teniposide, 50 mg \n 7035 \n \n $266.21 \n \n $53.24 \n \n \n Q2018 \n K \n \n Urofollitropin, 75 iu \n 7037 \n \n $44.73 \n \n $8.95 \n \n \n Q2019 \n K \n \n Basiliximab \n 1615 \n \n $1,473.45 \n \n $294.69 \n \n \n Q2020 \n E \n \n Histrelin acetate \n "}]}